Complex challenges in pain and opioid management: relevance to de-prescribing

Jessica Merlin MD, PhD, MBA Professor of Medicine with Tenure

@JessicaMerlinMD










Conflicts of Interest

• My research is funded in part by a grant to Pitt from the Cambia Health Foundation.








How I learned about de-prescribing

Older Patient and Caregiver Perspectives on Medication Value and Deprescribing: A Qualitative Study

Aimee N. Pickering, MD, * ^(D) Megan E. Hamm, PhD,[†] Alicia Dawdani, BS,[†] Joseph T. Hanlon, PharmD,^{$\ddagger \$ \parallel \parallel$} Carolyn T. Thorpe, PhD, MPH,^{$\parallel \ast \ast \parallel$} Walid F. Gellad, MD,^{$\dagger \$ \parallel \parallel$} and Thomas R. Radomski, MD^{$\dagger \$ \parallel \parallel \square$}







Dr. Tom Radomski





Perceived effectiveness







- Perceived effectiveness
 - Subjective improvement in symptoms

"I've always looked at it not... whether or not I needed it (the medication) beforehand, but whether or not it made me feel better afterward."

Aimee Hckenng,





- Perceived effectiveness
 - Subjective improvement in symptoms
 - Objective improvement in clinical values

"I know mine's (medication) working [because] I'm diabetic, because there's one point my A1C was 9.1... and now it's down to 6.1"

Aimee Hekening,





- Perceived effectiveness
 - Subjective improvement in symptoms
 - Objective improvement in clinical values
 - Disease prevention

"I wasn't really following up on all those medications... and then I ended up having another heart attack and then the reality set it and started taking my medications like I was supposed to..."

Aimee Hekening,





• Adverse effects on quality-of-life







- Adverse effects on quality-of-life
 - Severity of side effects

"I think if it's debilitating in any form like nausea, vomiting... diarrhea... [and the side effects] are going to impact your life... and your ability to do even basic things like leaving the house... that's when it's not worth it anymore...."

Aimee Hckenng,





- Adverse effects on quality-of-life
 - Severity of side effects
 - Inconvenience associated with administration

"I hate testing myself for my sugar every morning, and I don't do it every day... so I don't take insulin, like after my meals...."

Aimee Hekening,





- Adverse effects on quality-of-life
 - Severity of side effects
 - Inconvenience associated with administration
 - Discomfort associated with administration

"They put me on an injection which I did not like, and I tried that for a while and went back to the doctor and said I can't do this... I can't give myself injections...."

Aimee Hekening,





How these insights relate to opioid prescribing

- Patient perception of symptom improvement
- Many formulations and medications to address side effects
- Fairly convenient/comfortable to administer







Among patients (with or without HIV) in primary care prescribed opioids, what is the best way to manage misuse behaviors?





Opioid misuse in primary care

- Opioids are commonly prescribed for chronic pain¹
- Safe opioid prescribing requires careful attention to patient behavior
- "Misuse behaviors" are common in clinical practice²

1. Bohnert AS, Ann Int Med, 2018. 2. Vowles KE, Pain, 2015.



Opioid misuse in primary care

- May signal serious underlying (e.g., opioid use disorder)¹
- Unclear course of action
- Leads clinician dissatisfaction/ burnout^{3,4}
- Focus on identification of behaviors, *limited evidence* on how to respond when they arise

1. Fishbain DA et al, Pain Med, 2008. 2. Meltzer EC et al, Pain Med, 2012.

3. Dobscha SK et al, Pain Med, 2008. 4. Merlin JS et al, Pain Med, 2014.

Dr. Jessica Merlin



Delphi approach

- Developed by RAND during the cold war¹
- Used when there is a lack of evidence but an urgent need for guidance²
- Systematic approach to explore whether consensus exists, and if it does, to identify consensus beliefs among a diverse group of experts^{3,4}
- Widely accepted as a level of evidence that can drive policy and practice⁵

<u>1. https://en.wikipedia.org/wiki/Delphi_method</u>. 2. Keeney S, Wiley-Blackwell, 2011.

3. Barber CE, Arthritis Res Ther, 2015. 4. Khodyakov D, J Eval Clin Pract, 2017.

5. Khodyakov D, BMC Med Res Methodol, 2011.



- Participants recruited from expert groups who prescribe opioids and are self-reported experts
- Four online rounds:
 - 1. Brainstorm behaviors, pick 2 most common & 2 most challenging
 - 2. Asked about management of most important Round 1 behaviors

Merlin JS, BMJ Open, 2016.



3. Rate importance of Round 2 strategies on 1-9 scale. A priori rules:

- 1-3 "not important," 4-6 "uncertain," 7-9 "very important"
- <u>Disagreement:</u> ≥1/3 "not important" AND ≥1/3 "very important"
- <u>Consensus:</u> absence of disagreement
 - If consensus: median \geq 7 management strategy important,

≤ 3 not important, 4-6 uncertain importance

• Free-text clarification encouraged


Merlin JS, BMJ Open, 2016.



- 4. Developed cases:
 - Told participants all consensus approaches had been utilized
 - Highlighted branch points based on comments
 - If there was disagreement, provided prior round response and reasked question

Merlin JS, BMJ Open, 2016.





Round 1 participants:

- Female: 52%
- White: 83%
- Physicians: 71% (90% internists)
- Academic primary (40%) or specialty care (19%); 48% VA
- All US regions represented

The 6 most frequently cited common and challenging behaviors

- missing appointments
- taking opioids for symptoms other than pain
- using more opioid medication than prescribed
- asking for an increase in opioid dose
- and alcohol and other substance use

Merlin JS, *JGIM*, 2018. Young S, Merlin JS, *Pain Med*, 2019. Dr. Jessica Merlin




Common strategies across behaviors

- Do not immediately stop abruptly
- Patient education
- Determine if there is a pattern present and if there is an opioid use disorder
- If there is an opioid use disorder, treat it
- If there is a pattern but no opioid use disorder, weigh benefits vs. risks
- Consider tapering/stopping

Merlin JS, JGIM, 2018.









Taking opioids for symptoms other than pain

(i.e., for anxiety, depression, sleep, or to produce euphoria)

RECOMMENDED

- Detailed assessment to understand why patient is using the opioid for symptoms other than pain
- Explore differential diagnosis of potential underlying problems (e.g., depression)
- Patient education regarding appropriate and safe use of opioids
- Discuss or refer for non-opioid therapies (e.g., non-opioid pharmacologic therapies, nonpharmacologic therapies)
- Make a referral (e.g., to a psychologist, psychiatrist, or to an addiction treatment program)

Patient continues to take opioids for symptoms other than pain




CONSIDER Stop opioid therapy immediately





Stop opioid therapy immediately














Dr. Jessica Merlin







Why consider Opioid Tapering?

- Pain, function & quality of life <u>may improve</u> with voluntary opioid tapering supported by multidisciplinary team
- Sometimes needed in patients with opioid misuse behaviors when buprenorphine is not feasible

Frank et al (2017)

Disclaimer

- High-quality evidence on tapering-related harms is limited
 Can lead to withdrawal, psychological distress, unmasked OUD, increased pain
- Harm reduction
 - \odot Frequent check ins
 - \circ Short prescriptions
 - \circ Naloxone
 - o Interdisciplinary multimodal care.
- This is an area where new research is emerging.
- Policies make it challenging to provide individualized care

Larochelle et al (2021); Agnoli et al (2021)

'How to' on opioid tapering

- Tapers work best when combined with psychosocial support¹
- Give patient control over rate whenever possible
- One published example from a pain clinic:²

 Education, go slow, 5% reduction 2x/1 mo, then 10%/week max
 75% of patients enrolled, 38% of those completed the study
 Most completers reduced dose with minimal/no change in pain
- Switching to buprenorphine may also be a useful tapering tool^{3,4}
 Lower overdose risk: regardless of taper, the patient is safer

1. Frank (2017); 2. Darnell (2017); 3. Chou (2019)4. Powell (2021)



Buprenorphine Rotation

- Systematic Review: bup rotation a/w reduced pain
- Buprenorphine rotation may mitigate full agonist-related harms
 - E.g., inadequate analgesia, intolerable adverse effects, risky regimens (e.g., high dose), and opioid misuse
- Further studies needed to find ideal approach to bup rotation

Next steps (funded R34)

- Identify and operationalize implementation strategies for algorithms (short story: EHR integration, training, e-consults)
- Pilot trial





Key definitions

Serious illness: Carries a high risk of mortality AND either negatively impacts a person's daily function or quality of life, OR excessively strains their caregivers¹

Palliative care: care for people with serious illness focused on improving quality of life for patient and family²

Note: Palliative care has moved "upstream"³

1. Kelley AS, J Palliat Med, 2018. 2. www.capc.org. 3. Kelley AS, N Eng J Med, 2010.



Key definitions cont'd

Opioid misuse:

- missing appointments
- taking opioids for symptoms other than pain
- using more opioid medication than prescribed
- asking for an increase in opioid dose
- angry/aggressive behavior related to opioid
- alcohol and other substance use

Merlin JS, *JGIM*, 2018. Young S, Merlin JS, *Pain Med*, 2019.

Dr. Jessica Merlin



Opioid use disorder (OUD):

- Based on DSM-V criteria
- At the core: loss of control over opioid use, with important consequences



What are some of the most

important issues issues

related to pain and opioid

misuse/OUD in patients with

serious illness?





Qualitative study of opioid mgmt challenges in serious illness

- National pall care clinician sample online
- Asked 7 open-ended questions re: challenges
 - faced and decision-making
- Content analysis





Results: opioid mgmt challenges in serious illness

- •N=83
- 90% physicians
- •5% NP, 43% academic, 31% community





Prescriber challenges faced

Care approach differences

"Cancer survivors who are free of disease whose oncologist has been prescribing high dose opioids for N years, only to decide this is not a clinic for 'weaning'... patients not on board."



Decision-making

Factors related to disease or its treatment

When patient has curative intent of therapy, I am more conscious of the need to limit frequent escalations of medication due to future expectations to wean and/or stop opiate use in the future



Decision-making

Prognosis: two alternative viewpoints

"If the patient is likely to die, we are more lenient. If the patient is dying, we are the most lenient."

"Risks/harms and benefits don't go away or lessen if patient has a poor prognosis."





What is the best approach to the management of opioid misuse / use disorder in individuals with serious illness?





Modified Delphi Study to address this clinical question

- A Delphi study using expert panels can be conducted when no empirical evidence exists to answer a particular clinical question
 - Considered expert consensus-level evidence and may be used to generate clinical guidance
 - Determines whether consensus exists and if it exists, what it is

Shekelle PG, West J Med, 1999.



Methods

- 2 panels based on prognosis: weeks-months, months-years
- Developed common variations on scenario: 50 y/o, pain d/t cancer/treatment, unacceptable pain ctrl
- Participants: palliative care and addiction experts
- Rounds: 1) rate appropriateness of management strategies; 2) online review of R1 quantitative/qualitative results and discussion; 3) final rating

Merlin JS, JAMA Netw Open, 2021.




Results

- Of 129 invited experts: 120 (93%) participated in at least 1 round, 70 (84%) completed all 3 rounds
- Most of the experts held MD or DO degrees (115, 96%)

Merlin JS, JAMA Netw Open, 2021.







Merlin JS et al, JAMA Netw Open, 2021; Fitzgerald-Jones K, Merlin JS et al, JAMA Onc, 2022.

Dr. Jessica Merlin





Consensus on appropriateness of strategies to manage cancer-related pain with opioid use or use disorder

Meet the Patient Other pain therapies Advanced On active Pain related to Man in his 50s maximized, provided cancer cancer treatment cancer treatment with opioid education X 縱 പ്പം ċ/ Case 1 Case 2 Case 3 A recent history of opioid No history of OUD, No history of OUD, use disorder (OUD) who is prescribed traditional opioids prescribed traditional opioids not on OUD treatment and for pain, urine negative for for pain, then found to have prescribed opioids, and reports not yet prescribed opioids for pain. urine drug screens repeatedly positive repeatedly taking more opioids than for unprescribed benzodiazepines. prescribed. Recommendations **Recommendations** Recommendations regardless of prognosis regardless of prognosis regardless of prognosis Prescribe buprenorphine/ Increase monitoring Increase monitoring naloxone Refer to a methadone clinic Taper opioids **Continue opioids** Begin split doses of methadone? Transition to Taper opioids buprenorphine/naloxone Short prognosis Increase opioids based Transition to on what patients report buprenorphine/naloxone thev need Longer prognosis Begin a full opioid agonist other than methadone? Short prognosis Longer prognosis

Merlin JS et al, JAMA Netw Open, 2021; Fitzgerald-Jones K, Merlin JS et al, JAMA Onc, 2022.

Dr. Jessica Merlin





Stimulant cases





Conclusions

- Experts favored NOT de-prescribing OUD treatment even at EOL
- De-prescribing opioids is an option but often avoided if possible
- Choice between bup/nx and methadone is complex
- Intriguing results regarding methadone prescribing and the role of methadone clinics

Merlin JS, JAMA Netw Open, 2021.



Next steps (pending K24)

- Identify and operationalize implementation strategies for management approaches
- Pilot trial





(Some) future directions

- Optimize opioid decision-making in individuals with serious illness
- Implement evidence-based practices for opioid misuse/OUD in patients with serious illness
- Improve care for individuals with comorbid OUD and pain in primary care and opioid treatment settings: IMPOWR
- Improve cannabis decision-making and communication
- Mentor the next generation of investigators in OUD/pain
- Continue to collaborate with amazing people





Thank you, amazing people!

Pitt

- Jane Liebschutz
- Hailey Bulls
- Deanna Wilson
- Our amazing staff

Montefiore

- Joanna Starrels
- Julia Arnsten
- Deepika Slawek

OHSU

- Ben Morasco
- Shannon Nugent
- Devan Kansagara

Yale

- Will Becker
- Jen Edelman
- Jen Kapo
- Bob Kerns
- UAB
 - Mike Saag
 - Greer Burkholder

Others

- Diane Meier
- Christine Ritchie
- Mallory Johnson
- Judy Paice
- Katie Fitzgerald-Jones

...and many more!